269 related articles for article (PubMed ID: 9450554)
21. Crystallization of soluble urokinase receptor (suPAR) in complex with urokinase amino-terminal fragment (1-143).
Huang M; Mazar AP; Parry G; Higazi AA; Kuo A; Cines DB
Acta Crystallogr D Biol Crystallogr; 2005 Jun; 61(Pt 6):697-700. PubMed ID: 15930623
[TBL] [Abstract][Full Text] [Related]
22. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.
Ploug M; Ostergaard S; Hansen LB; Holm A; Danø K
Biochemistry; 1998 Mar; 37(11):3612-22. PubMed ID: 9521680
[TBL] [Abstract][Full Text] [Related]
23. Plasminogen activator inhibitors regulate cell adhesion through a uPAR-dependent mechanism.
Czekay RP; Loskutoff DJ
J Cell Physiol; 2009 Sep; 220(3):655-63. PubMed ID: 19472211
[TBL] [Abstract][Full Text] [Related]
24. A soluble form of the urokinase plasminogen activator receptor (suPAR) can bind to hematopoietic cells.
Mizukami IF; Todd RF
J Leukoc Biol; 1998 Aug; 64(2):203-13. PubMed ID: 9715260
[TBL] [Abstract][Full Text] [Related]
25. Regulation of the uPAR/uPA system expressed on monocytes by the deactivating cytokines, IL-4, IL-10 and IL-13: consequences on cell adhesion to vitronectin and fibrinogen.
Paysant J; Vasse M; Soria J; Lenormand B; Pourtau J; Vannier JP; Soria C
Br J Haematol; 1998 Jan; 100(1):45-51. PubMed ID: 9450789
[TBL] [Abstract][Full Text] [Related]
26. Urokinase receptor-dependent upregulation of smooth muscle cell adhesion to vitronectin by urokinase.
Chang AW; Kuo A; Barnathan ES; Okada SS
Arterioscler Thromb Vasc Biol; 1998 Dec; 18(12):1855-60. PubMed ID: 9848876
[TBL] [Abstract][Full Text] [Related]
27. A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor.
Rettenberger P; Wilhelm O; Oi H; Weidle UH; Goretzki L; Koppitz M; Lottspeich F; König B; Pessara U; Kramer MD
Biol Chem Hoppe Seyler; 1995 Oct; 376(10):587-94. PubMed ID: 8590627
[TBL] [Abstract][Full Text] [Related]
28. Critical role of integrin alpha 5 beta 1 in urokinase (uPA)/urokinase receptor (uPAR, CD87) signaling.
Tarui T; Andronicos N; Czekay RP; Mazar AP; Bdeir K; Parry GC; Kuo A; Loskutoff DJ; Cines DB; Takada Y
J Biol Chem; 2003 Aug; 278(32):29863-72. PubMed ID: 12754207
[TBL] [Abstract][Full Text] [Related]
29. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide.
Llinas P; Le Du MH; Gårdsvoll H; Danø K; Ploug M; Gilquin B; Stura EA; Ménez A
EMBO J; 2005 May; 24(9):1655-63. PubMed ID: 15861141
[TBL] [Abstract][Full Text] [Related]
30. Random peptide bacteriophage display as a probe for urokinase receptor ligands.
Fong S; Doyle MV; Goodson RJ; Drummond RJ; Stratton JR; McGuire L; Doyle LV; Chapman HA; Rosenberg S
Biol Chem; 2002 Jan; 383(1):149-58. PubMed ID: 11928809
[TBL] [Abstract][Full Text] [Related]
31. Sequences within domain II of the urokinase receptor critical for differential ligand recognition.
Li Y; Lawrence DA; Zhang L
J Biol Chem; 2003 Aug; 278(32):29925-32. PubMed ID: 12761227
[TBL] [Abstract][Full Text] [Related]
32. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect.
Resnati M; Guttinger M; Valcamonica S; Sidenius N; Blasi F; Fazioli F
EMBO J; 1996 Apr; 15(7):1572-82. PubMed ID: 8612581
[TBL] [Abstract][Full Text] [Related]
33. Intermolecular contact regions in urokinase plasminogen activator receptor.
Liang OD; Bdeir K; Matz RL; Chavakis T; Preissner KT
J Biochem; 2003 Nov; 134(5):661-6. PubMed ID: 14688231
[TBL] [Abstract][Full Text] [Related]
34. Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region.
Gårdsvoll H; Ploug M
J Biol Chem; 2007 May; 282(18):13561-72. PubMed ID: 17355965
[TBL] [Abstract][Full Text] [Related]
35. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
[TBL] [Abstract][Full Text] [Related]
36. Domain 1 of the urokinase receptor (uPAR) is required for uPAR-mediated cell binding to vitronectin.
Sidenius N; Blasi F
FEBS Lett; 2000 Mar; 470(1):40-6. PubMed ID: 10722842
[TBL] [Abstract][Full Text] [Related]
37. Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system.
Stahl A; Mueller BM
Int J Cancer; 1997 Mar; 71(1):116-22. PubMed ID: 9096674
[TBL] [Abstract][Full Text] [Related]
38. Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies.
Rasch MG; Pass J; Illemann M; Høyer-Hansen G; Lund IK
J Immunol Methods; 2008 Nov; 339(1):55-65. PubMed ID: 18761343
[TBL] [Abstract][Full Text] [Related]
39. Cell-surface acceleration of urokinase-catalyzed receptor cleavage.
Høyer-Hansen G; Ploug M; Behrendt N; Rønne E; Danø K
Eur J Biochem; 1997 Jan; 243(1-2):21-6. PubMed ID: 9030717
[TBL] [Abstract][Full Text] [Related]
40. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin.
Waltz DA; Natkin LR; Fujita RM; Wei Y; Chapman HA
J Clin Invest; 1997 Jul; 100(1):58-67. PubMed ID: 9202057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
